Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program

Journal of Managed Care Pharmacy

Volumn 12, Issue 6, 2006, Pages 466-471

  Lawrence, David B ^a   Ragucci, Kelly R ^b   Long, Laura B ^c   Parris, Beth S ^d   Helfer, Lisa A ^d  

^a PFIZER INC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BlueChoice HealthPlan   (United States)

^d BlueChoice HealthPlan   (United States)

Author keywords

Adherence; Diabetes; Disease management; Hemoglobin A1c; Managed care; Medication possession ratio; Metformin; Sulfonylurea

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE MANAGEMENT; HEALTH MAINTENANCE ORGANIZATION; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL RECORD; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; BLOOD; COMPARATIVE STUDY; DISEASE MANAGEMENT; DRUG COMBINATION; EVALUATION; METABOLISM; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; DIABETES MELLITUS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PATIENT COMPLIANCE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SOUTH CAROLINA; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 34347402186     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.6.466     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2004. Rev ed. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-53.
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4-S33.
6. DiMatteo MRP. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004:42:200-09.
7. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004:27:1218-24.
8. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27:2800-05.
9. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004;38(9):1357-62.
10. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25:1015-21.
11. Day D. Use of pharmacy claims databases to determine rates of medication adherence. Adv Ther. 2003;20:164-76.
12. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4-S33.
13. Glasgow RE, McCaul KD, Schafer LC. Self-care behaviors and glycemic control in type 1 diabetes. J Chron Dis. 1987:40:399-412.
14. Kravitz RL, Hays RD, Sherbourne CD, et al. Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med. 1993;153:1869-78.
15. Wooldridge KL, Wallston KA, Graber AL, et al. The relationship between health beliefs, adherence and metabolic control of diabetes. Diabetes Educ. 1992;18:495-500.
16. Hays RD, Kravitz RL, Mazel RM, et al. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. J Behav Med. 1994;17:347-60.
17. Dalewitz J, Khan N, Hershey CO. Barriers to control of blood glucose in diabetes mellitus. Am J Med Qual. 2000;15:16-25.
18. Diehl AK, Bauer RL, Sugarek NJ. Correlates of medication compliance in non-insulin-dependent diabetes mellitus. South Med J. 1987;80:332-35.
19. Chousa FP, Guillen VFG, Otero MD, Beltran DO, Lopez RP, Sanchez JM. Usefulness of six indirect methods to evaluate drug therapy compliance in non-insulin dependent diabetes mellitus. Revista Clinica Espanola. 1997;197:555-59.
20. Peterson GM, McLean S, Senator GB. Determinants of patient compliance, control, presence of complications and handicap in non-insulin-dependent diabetes. Aust N Z J Med. 1984;14:135-41.
21. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27:2149-53.
22. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-30.
23. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;10:144-51.
24. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25:2958-71.
25. American College of Endocrinology: Consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8(suppl 1):5-11.
26. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicare beneficiaries with schizophrenia. Am J Psychiatr. 2004;162(4):692-99.
27. Reasner CA, Goke B. Overcoming the barriers to effective glycemic control for type 2 diabetes. Br J Diabetes Vasc Dis. 2002;2:290-95.
28. Blandford L, Dans PE, Ober JD, Wheelock C. Analyzing variations in medication compliance related to individual drug, drug class and prescribing physician. J Manag Care Pharm. 1999;5(1):47-51.
29. Hsaio LD, Salmon JW. Predicting adherence to prescription medication purchase among HMO enrollees with diabetes. J Manag Care Pharm. 1999;5(4):336-41.